Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 3/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9815841 | 0.84 | L3MBTL1 (0.57) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL984297 | 0.84 | L3MBTL1 (0.57) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL4374949 | 0.82 | L3MBTL1 (0.59) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL11581518 | 0.82 | L3MBTL1 (0.55) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL140814 | 0.82 | ALDH1A1 (0.57) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL286760 | 0.81 | IDO1 (0.57) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL9375354 | 0.81 | L3MBTL1 (0.54) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL2659085 | 0.81 | RAB9A (0.57) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL28837976 | 0.81 | L3MBTL1 (0.54) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL7086104 | 0.79 | L3MBTL1 (0.53) | L3MBTL1CASP3SENP8SENP7SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210071181-A1 | PHARMACEUTICAL COMPOSITION | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2021-03-11 | — | — | US | disclosed |
| EP-3502255-A1 | PHARMACEUTICAL COMPOSITION | Roche Innovation Center Copenhagen A/S (DK) | 2019-06-26 | — | — | EP | disclosed |
| US-20190071672-A1 | Pharmaceutical Composition | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-03-07 | — | — | US | disclosed |
| EP-3431602-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-MIRNA ANTISENSE OLIGONUCLEOTIDES | Roche Innovation Center Copenhagen A/S (DK) | 2019-01-23 | — | — | EP | disclosed |
| EP-2666859-B1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-MIRNA ANTISENSE OLIGONUCLEOTIDES | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2019-01-02 | — | — | EP | disclosed |
| US-20180195062-A1 | Pharmaceutical Composition | SANTARIS PHARMA A/S (DK) | 2018-07-12 | — | — | US | disclosed |
| EP-2264172-B1 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF HIF-1ALPHA EXPRESSION | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2017-09-27 | — | — | EP | disclosed |
| US-9738894-B2 | Short interfering RNA (siRNA) analogues | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2017-08-22 | — | — | US | disclosed |
| US-20170009237-A1 | Short Interfering RNA (siRNA) Analogues | SANTARIS PHARMA A/S (DK) | 2017-01-12 | — | — | US | disclosed |
| EP-2141234-B1 | Short Interfering RNA (siRNA) Analogues | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2016-04-27 | — | — | EP | disclosed |
| EP-1501930-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION HIF-1ALPHA EXPRESSION | Santaris Pharma A/S (DK) | 2005-02-02 | — | — | EP | disclosed |
| US-20050014712-A1 | Oligomeric compounds for the modulation survivin expression | ENZON PHARMACEUTICALS, INC | 2005-01-20 | — | — | US | disclosed |
| US-20040248840-A1 | Oligomeric compounds for the modulation of ras expression | SANTARIS PHARMA A/S | 2004-12-09 | — | — | US | disclosed |
| US-20040241717-A1 | Oligomeric compounds for the modulation of thioredoxin expression | SANTARIS PHARMA A/S | 2004-12-02 | — | — | US | disclosed |
| WO-2004083430-A2 | SHORT INTERFERING RNA (siRNA) ANALOGUES | SANTARIS PHARMA A/S (DK) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004069991-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069990-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDOXIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069992-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF RAS EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| US-20040096848-A1 | Oligomeric compounds for the modulation HIF-1alpha expression | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2004-05-20 | — | — | US | disclosed |
| WO-2003085110-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION HIF-1ALPHA EXPRESSION | SANTARIS PHARMA A/S (DK) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248840-A1 | Oligomeric compounds for the modulation of ras expression | HRAS, KRAS, NRAS | L3MBTL1 388/4885CASP3 3909/4885SENP8 1334/4885 |
| US-20040241717-A1 | Oligomeric compounds for the modulation of thioredoxin expression | TXN, TXN2, TXNRD3 | L3MBTL1 109/4885CASP3 3082/4885SENP8 1747/4885 |
| US-20040096848-A1 | Oligomeric compounds for the modulation HIF-1alpha expression | HIF1AN, HIF1A, HYOU1 | L3MBTL1 156/4885CASP3 2898/4885SENP8 1914/4885 |
| US-20050014712-A1 | Oligomeric compounds for the modulation survivin expression | BIRC5, XIAP, BIRC3 | L3MBTL1 67/4885CASP3 187/4885SENP8 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.